Parabilis Medicines (Series F)
Funding Details
Awarder
Inbox
Date Award
January 12, 2026
Vertical
Biopharmaceuticals
Funding Amount
$305,000,000
Company Info
Market
Clinical-stage biopharmaceuticals
Location
Cambridge, MA, USA
Coinvestors
ARCH Venture Partners, Cormorant Asset Management, Fidelity Management & Research Company, Frazier Life Sciences, General Catalyst Partners, Janus Henderson Investors, Nextech Invest, RA Capital Management, Soleus Capital, VenBio
Company Description

Parabilis Medicines is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines that unlock high-impact protein targets long-considered undruggable. Leveraging over a decade of proprietary data, laboratory innovations, and AI- and physics-based algorithms, the company has developed a new class of stabilized, cell-penetrant alpha-helical peptides - Helicons™ - capable of modulating intracellular proteins that are inaccessible to traditional drug modalities.

Links